FDA approves Pfizer's supplemental new drug application for CIBINQO
Label expansion for CIBINQO provides new systemic oral option for adolescents (12 to <18 years) with moderate-to-severe atopic dermatitis
Label expansion for CIBINQO provides new systemic oral option for adolescents (12 to <18 years) with moderate-to-severe atopic dermatitis
The Innovation Explorer database of GlobalData’s Disruptor Intelligence Center highlights the key company collaborations in pharma to advance AI-powered drug repurposing techniques.
Diagnostic imaging will become an increasingly vital process in healthcare
OmiCrisp has been developed with support from Centre for Cellular And Molecular Platforms C-CAMP-InDx Program
The cardiomyopathies market in the 68M is set to grow at a CAGR of 12.1%
Partnership to leverage the Helix Laboratory Platform and QIAGEN's biopharma relationships, NGS capabilities, and global regulatory expertise
This ambitious anti-TB campaign, as part of IOCL’s CSR, aims to ensure early identification of presumptive TB and prompt diagnosis using high-sensitivity diagnostic tests at the doorstep
The investment will enable the company to enter European markets as well as enhance margins in current markets
Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial
The yoga protocol included gentle and restorative yoga postures(asana) with regular periods of relaxation and pranayama
Subscribe To Our Newsletter & Stay Updated